Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000696

Enrollment

228

Registered

2013-03-06

Start date

2013-05-27

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Biological/Vaccine, Non-Stem Cell : Recombinant human erythropoietin (rHuEPO) 500 IU/kg is administered intravenously for 10 minutes immediately after anestehtic induction to erythropoietin gr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -normal renal function (serum creatinine < 1.3 mg/dl) -anemic patient (Hgb < 13 g/dl in men, Hgb < 12 g/dl in women accoridng to World Health Organization criteria) -elective surgery -20 years old or more than 20 years old -patient who agree to participate the present clinical study voluntarily

Exclusion criteria

Exclusion criteria: -non-animic patient ( Hgb = 13 g/dl in men, Hgb = 12 g/dl in women) -uncontrolled hypertension ( diastolic blood presusre > 100 mmHg) -platelet > 450,000/mm3 -history of thromboembolism -concomitant cancer -chronic use of erythropoietin -patient who disagree to paricipate the present study voluntarily -emergency surgery -chronic kidney disease or serum creatinine = 1.3 mg/dl -preoperative inotropic support

Design outcomes

Primary

Measure	Time frame
serum creatinine	—

Secondary

Measure	Time frame
cardiovascular function by SOFA (sequential organ failure assessment) score	—

Countries

Korea, Republic of

Contacts

Public ContactJi-Hyun Chin

Asan Medical Center

Outcome results